查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1808421

生物標記檢測服務市場（按服務類型、技術、應用和最終用戶）—2025-2030 年全球預測

Biomarker Testing Services Market by Service Type, Technology, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計生物標記檢測服務市場在 2024 年的價值將達到 10.6 億美元，在 2025 年成長至 11.3 億美元，在 2030 年達到 16.2 億美元，複合年成長率為 7.38%。

主要市場統計數據
基準年2024年 10.6億美元
預計2025年 11.3億美元
預測年份 2030 16.2億美元
複合年成長率（%） 7.38%

生物標記檢測服務的全面定位，描述了影響臨床和轉化應用的科學基礎、相關人員生態系統和業務必要事項

生物標記檢測服務處於實驗室科學、臨床決策和藥物研發之間的關鍵交匯點。這些服務涵蓋實驗室工作流程、分析和臨床驗證、法規遵循以及數據解讀，這些服務共同促進診斷明確、患者分層和治療監測。相關人員包括發現新型標記的學術研究人員、提供診斷結果的臨床實驗室、將檢測方法整合到研發項目中的受託研究機構，以及依賴強力的生物標記證據來指南藥物研發和臨床試驗設計的生物製藥公司。

技術進步、監管加強和權力下放如何重新定義生物標記檢測服務供應商的差異化和臨床價值

在技​​術、臨床和監管趨勢融合的推動下，生物標記檢測服務格局正在改變。序列測定使得更深入的分子表徵成為可能，而生物資訊學和數據平台的改進則將高維度輸出轉化為可操作的臨床和開發洞察。因此，檢測服務的價值提案正在從單一的分析讀數擴展到綜合的診斷敘述，為治療選擇和試驗分層提供資訊。

評估 2025 年實施的美國關稅調整的營運和策略影響，以及它們將如何影響採購、採購和服務連續性

2025年實施的美國關稅的累積效應正在對生物標記檢測供應鏈中的多個環節施加特定壓力，促使供應商重新評估其採購、成本模型和庫存策略。進口關稅及相關的海關手續複雜化，導致通常透過跨境製造商採購的關鍵檢測設備、試劑和耗材的到岸成本上升。這使得企業必須消化更高的投入成本，重新協商供應商契約，或在貿易關係更為有利的司法管轄區尋找替代供應商。

詳細的細分洞察揭示了服務類型、技術平台、應用重點和最終用戶期望如何影響競爭地位和投資重點

細分市場動態揭示了跨服務類型、技術、應用和最終用戶的清晰差異化路徑，從而塑造了競爭定位和成長機會。按服務類型細分，服務供應商擴大將分析檢測服務與臨床實驗室服務相結合，以彌合藥物研發與患者照護之間的差距。雖然客製化和合約服務對於外包專業檢測開發和驗證仍然至關重要，但由於核准標準日益嚴格，監管和合規服務正日益成為差異化因素。

區域比較評估，展示能力叢集、監管差異和製造地如何影響美洲、歐洲、中東和非洲以及亞太地區的戰略選擇

區域動態對產能分佈、監管格局和夥伴關係模式產生顯著影響，從而在三大區域創造了差異化的業務成果。在美洲，臨床實驗室網路和成熟的生物製藥生態系統支持伴隨診斷和高可及性檢測的快速應用，而私人和公共投資則持續支持轉化研究夥伴關係。該地區還面臨與關稅相關的供應鏈調整，這些調整會影響試劑和設備的採購。

競爭策略和合作夥伴生態系統洞察顯示垂直整合、平台互通性和卓越驗證如何決定供應商對臨床和製藥客戶的吸引力

主要企業之間的競爭動態體現了垂直整合、平台專業化和協作生態系統之間的平衡。儀器製造商持續投資於提高靈敏度、通量和互通性，以鎖定平台的採用。同時，試劑和耗材供應商強調品管和法規支持，以深化與實驗室的夥伴關係。以服務為中心的組織，包括專業的合約研究和臨床檢測供應商，透過快速的周轉、臨床驗證專業知識和可擴展的營運來適應高度複雜的工作流程，從而脫穎而出。

切實可行的優先策略行動，幫助供應商增強韌性，加速臨床整合，並透過數據、夥伴關係和監管準備實現差異化

產業領導者應採取一系列切實可行的行動，以增強韌性、加速應用並獲得差異化價值。首先，優先投資生物資訊學和數據平台能力，以實現對分子和蛋白質檢測的可靠解讀和彙報。其次，多元化籌資策略，減少對單一供應商和易受關稅影響的進口機會的依賴，同時開發合格的替代供應商，並保持關鍵試劑和組件的連續性。

強力的調查方法結合了主要相關人員訪談、多來源二次審查和技術三角測量，提供了寶貴的見解並強調了證據的局限性。

本執行摘要依據的研究整合了主要相關人員訪談、多來源二次分析以及嚴格的三角檢驗，以確保其可靠性和有效性。主要輸入包括對實驗室主任、臨床研究人員、臨床實驗負責人和技術供應商的深入訪談，以獲取關於營運挑戰、技術採用促進因素和監管痛點的第一手觀點。這些質性見解也輔以同儕審查文獻、監管指南文件、技術白皮書和公司揭露文件的系統性回顧，以檢驗技術趨勢和照護標準的變化。

結論強調，技術投資、營運適應性和臨床夥伴關係關係對於生物標記檢測服務領域持續保持領先地位至關重要

生物標記檢測服務的下一階段將惠及那些將卓越技術與適應性運作模式和深度臨床夥伴關係相結合的機構。在進階分析技術的支持下，高解析度分子和蛋白質組學平台正在擴展證明診斷效用的標準，並實現更精準的治療關聯。同時，供應鏈壓力和日益成長的監管期望迫使供應商仔細考慮採購、檢驗途徑和資料管治。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 液態生物檢體技術在照護端早期癌症檢測的快速應用
  • 將人工智慧和機器學習演算法整合到新型生物標記發現流程中
  • 擴大多重生物標記組合的供應，用於全面的疾病分析
  • 伴隨診斷對於個人化腫瘤治療途徑變得越來越重要
  • 開發用於分散臨床試驗的照護現場生物標記檢測平台
  • 增加基因組和蛋白質體生物標記的投資，以精準選擇免疫療法
  • 監管協調努力加速全球生物標記測試的核准和市場進入
  • 數位病理學和影像分析在生物標記檢測工作流程中的應用日益增多
  • 用於持續監測生物標記的新興非侵入式穿戴式生物感測器平台
  • 生物技術公司和診斷實驗室之間的合作正在不斷增多，以促進高通量生物標記篩檢

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第8章生物標記檢測服務市場（依服務類型）

  • 分析測試服務
  • 臨床檢測服務
  • 客製化和合約服務
  • 監理與合規服務

9. 生物標記檢測服務市場（依技術）

  • 生物資訊學和數據平台
  • 基於細胞的檢測
  • 分子技術
    • 原位雜合技術
      • 顯色原位雜合反應（CISH）
      • 螢光原位雜合反應（FISH）
    • 微陣列
    • 次世代定序（NGS）
    • 聚合酵素鏈鎖反應（PCR）
      • 數位PCR
      • 定量聚合酵素鏈鎖反應（qPCR）
  • 基於蛋白質的技術
    • 流式細胞技術
    • 免疫檢測
      • 酵素免疫分析法（ELISA）
      • 蛋白質印跡法
    • 質譜法
      • LC-MS/MS
      • MALDI-TOF

第 10 章生物標記檢測服務市場（按應用）

  • 伴隨診斷
    • 腫瘤學
    • 個人化醫療
  • 疾病診斷
    • 心血管系統
    • 感染疾病
    • 腫瘤學
  • 藥物開發
    • 臨床試驗
    • 發現
    • 毒理學

第 11 章。生物標記檢測服務市場（按最終用戶）

  • 學術研究機構
  • 合約研究組織
  • 醫院和診斷實驗室
  • 製藥和生物技術公司

12.美洲生物標記檢測服務市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

13. 歐洲、中東和非洲生物標記檢測服務市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

14.亞太生物標記檢測服務市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第15章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Avid Bioservices, Inc.
    • Agilent Technologies, Inc.
    • BioAgilytix Labs
    • BiomarkerBay BV
    • Bristol Myers Squibb
    • Eurofins Scientific SE
    • F. Hoffmann-La Roche AG
    • Icon PLC
    • Intertek Group PLC
    • IQVIA
    • JSR Life Sciences, LLC
    • Laboratory Corporation of America Holdings
    • LGC Group
    • Merck KGaA
    • NeoGenomics Laboratories
    • Parexel International Corporation
    • SGS SA
    • Shuwen Biotech Co., Ltd.
    • Syneos Health
    • Thermo Fisher Scientific, Inc.
    • WuXi Biologics Inc.
    • PerkinElmer Inc.
    • KCAS Group
    • Randox Laboratories
    • Myriad Genetics, Inc.
    • Bio-Rad Laboratories, Inc.

第16章 研究人工智慧

第17章 研究統計

第18章 研究聯絡人

第19章 研究報導

第20章 附錄

Product Code: MRR-B16853779DF0

The Biomarker Testing Services Market was valued at USD 1.06 billion in 2024 and is projected to grow to USD 1.13 billion in 2025, with a CAGR of 7.38%, reaching USD 1.62 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.06 billion
Estimated Year [2025] USD 1.13 billion
Forecast Year [2030] USD 1.62 billion
CAGR (%) 7.38%

Comprehensive orientation to biomarker testing services describing the scientific foundations, stakeholder ecosystem, and operational imperatives shaping clinical and translational adoption

Biomarker testing services occupy a pivotal intersection between laboratory science, clinical decision-making, and pharmaceutical development. These services encompass laboratory workflows, analytical and clinical validation, regulatory compliance, and data interpretation that collectively enable diagnostic clarity, patient stratification, and therapeutic monitoring. Stakeholders include academic researchers who explore novel markers, clinical laboratories that deliver diagnostic results, contract research organizations that embed assays into development programs, and biopharma companies that rely on robust biomarker evidence to guide drug discovery and clinical trial design.

The ecosystem is defined by rapid technological progress and growing expectations for translational impact. As a result, service providers are expected to deliver not only analytical precision but also integrated data management, reproducibility across platforms, and adherence to complex regulatory frameworks. Interoperability, sample logistics, and reagent quality are persistent operational considerations that influence laboratory throughput and clinical utility. At the same time, the shift towards personalized medicine increases demand for companion diagnostics and expanded panels, requiring service providers to scale assay diversity while ensuring clinical-grade performance.

Consequently, leaders in this space must balance technological investment with partnership strategies that prioritize speed, quality, and regulatory readiness. The remainder of this executive summary outlines the structural shifts reshaping supply chains and technology adoption, the implications of recent trade policy changes, segmentation-driven insights, regional dynamics, competitive positioning, and practical recommendations for action.

How converging technological advances, regulatory elevation, and operational decentralization are redefining provider differentiation and clinical value in biomarker testing services

The landscape for biomarker testing services is undergoing transformative shifts driven by converging technological, clinical, and regulatory trends. Advances in high-throughput sequencing, digital PCR, and mass spectrometry are enabling deeper molecular characterization, while simultaneous improvements in bioinformatics and data platforms are converting high-dimensional outputs into actionable clinical and developmental insights. As a result, the value proposition of testing services has expanded beyond single-analyte readouts to integrated diagnostic narratives that inform treatment selection and trial stratification.

In parallel, there is a steady migration of testing capacity towards decentralized and hybrid models that combine centralized high-complexity laboratories with point-of-care or near-patient solutions. This reconfiguration responds to clinical demand for faster turnaround and to commercial pressure to capture earlier points of care. Moreover, automation and laboratory information management systems are streamlining workflows, improving reproducibility, and reducing manual handling risks, which collectively raises expectations for consistent quality across service providers.

Regulatory scrutiny is intensifying, particularly for companion diagnostics and tests intended to support therapeutic claims. Providers must therefore invest in rigorous analytic and clinical validation programs, document traceability, and compliance infrastructure. Meanwhile, cross-sector collaborations among instrument manufacturers, reagent suppliers, bioinformatics vendors, and clinical partners are accelerating productization and reducing time from assay concept to clinical deployment. Taken together, these shifts necessitate strategic choices about where to differentiate-whether through technological leadership, platform integration, vertical service breadth, or regulatory expertise.

Assessment of the operational and strategic consequences of the United States tariff adjustments introduced in 2025 and how they reverberate through procurement, sourcing, and service continuity

The cumulative effect of United States tariffs implemented in 2025 has exerted tangible pressure across multiple nodes of the biomarker testing supply chain, prompting providers to reevaluate sourcing, cost models, and inventory strategies. Import duties and associated customs complications have increased landed costs for critical laboratory instruments, reagents, and consumables that are commonly sourced through cross-border manufacturers. This has produced an operational imperative to either absorb higher input costs, renegotiate supplier agreements, or identify alternate suppliers in jurisdictions with more favorable trade relationships.

In practice, laboratories and contract service organizations have adopted a mix of strategies to mitigate tariff-driven disruption. Some have invested in inventory buffering and longer procurement cycles to smooth supply volatility, while others have increased engagement with domestic manufacturers to reduce reliance on tariff-exposed imports. Concurrently, instrument vendors that rely on global component sourcing have responded by redesigning procurement footprints, localizing certain assembly processes, or adjusting distribution pricing to preserve service contracts.

Beyond direct cost effects, tariffs have influenced strategic decision-making around capital expenditure and contractual commitments. Clinical partners and developers have become more cautious in committing to long-term platform rollouts without clearer visibility on total cost of ownership. Finally, the tariff environment has reinforced the importance of flexibility-providers that can reconfigure assays across platforms, qualify multiple reagent suppliers, and maintain fluid logistics arrangements are better positioned to sustain service continuity under evolving trade policies.

Detailed segmentation-driven insights revealing how service type, technological platforms, application focus, and end-user expectations converge to define competitive strengths and investment priorities

Segment-level dynamics reveal distinct pathways for differentiation across service types, technologies, applications, and end users that shape competitive positioning and growth opportunity. Service providers classified by service type increasingly combine analytical testing services with clinical testing offerings to bridge discovery and patient care; custom and contract services remain essential for specialized assay development and outsourced validation, while regulatory and compliance services are growing as a differentiator given heightened approval standards.

Technological segmentation highlights the centrality of bioinformatics and data platforms as enablers of complex assay interpretation, with cell-based assays complementing molecular approaches in functional characterization. Within molecular technologies, next-generation sequencing continues to be paired with in situ hybridization techniques such as chromogenic and fluorescence modalities to provide spatially resolved genomic context, and PCR modalities including digital PCR and quantitative PCR are being used for sensitive quantitation and validation. Protein-based technologies such as flow cytometry, immunoassays including ELISA and Western blot, and mass spectrometry platforms like LC-MS/MS and MALDI-TOF are deployed for orthogonal validation and biomarker verification.

Application-driven segmentation underscores the prominence of companion diagnostics in oncology and personalized medicine, while disease diagnosis workflows span cardiovascular, infectious disease, and oncology use cases. Drug development workflows leverage biomarker services across clinical trials, discovery programs, and toxicology assessments. Finally, end users range from academic and research institutes to contract research organizations, hospitals and diagnostics labs, and pharmaceutical and biotechnology companies, each demanding different service level agreements, turnaround expectations, and data governance arrangements. Taken together, these layered segmentation perspectives inform where providers should invest in capabilities to serve differentiated client needs.

Comparative regional evaluation showing how capability clusters, regulatory variation, and manufacturing footprints in the Americas, Europe, Middle East & Africa, and Asia-Pacific shape strategic choices

Regional dynamics exert a pronounced influence on capability distribution, regulatory landscapes, and partnership models, creating differentiated operating realities across the three principal geographies. In the Americas, clinical laboratory networks and a mature biopharma ecosystem support rapid uptake of companion diagnostics and high-complexity assays, while robust private and public investment continues to underwrite translational research partnerships. This region also contends with tariff-related supply chain adjustments that affect reagent and instrument sourcing.

In Europe, Middle East & Africa, regulatory harmonization across jurisdictions and strong academic-industrial linkages facilitate multicenter validation efforts and cross-border clinical collaborations. Healthcare system heterogeneity within this region, however, creates variability in reimbursement pathways and adoption timelines, prompting providers to design flexible commercial models that accommodate diverse payer environments. Additionally, centers of excellence in genomics and proteomics provide competitive assets for service specialization.

The Asia-Pacific landscape is marked by rapid capacity expansion, growing domestic manufacturing capability for instruments and reagents, and rising demand from large patient populations. This region increasingly attracts investment for localized production and serves as an alternative sourcing hub that can buffer against tariff-related disruptions elsewhere. Collectively, these regional characteristics inform distribution strategies, alliance formation, and localized service offerings; providers that align operational footprints with regional strengths will be better positioned to serve global clients while managing regulatory and logistical complexity.

Insight into competitive strategies and partner ecosystems where vertical integration, platform interoperability, and validation excellence determine provider attractiveness to clinical and pharmaceutical clients

Competitive dynamics among leading companies reflect a balance between vertical integration, platform specialization, and collaborative ecosystems. Instrument manufacturers continue to invest in enhancing sensitivity, throughput, and interoperability to lock in platform adoption, while reagent and consumables suppliers emphasize quality control and regulatory support to deepen laboratory partnerships. Service-focused organizations, including specialized contract research and clinical testing providers, differentiate through rapid turnaround, clinical validation expertise, and scalable operations that accommodate high-complexity workflows.

Strategic alliances and acquisition activity are common mechanisms for capability extension, enabling companies to combine instrumentation, assay reagents, and data platforms into bundled offerings that simplify procurement for clinical and pharmaceutical clients. At the same time, niche providers with deep technical expertise in assay development or regulatory pathways retain high relevance for bespoke projects and translational collaborations. In addition, growing investment in digital analytics and interpretive software is reshaping the competitive landscape by creating opportunities for subscription-based services and value-added reporting.

Ultimately, commercial success depends on articulating clear value propositions that address clinical utility, reproducibility, and regulatory readiness. Firms that can demonstrate rigorous validation, seamless data integration, and flexible service models are most attractive to clients seeking to accelerate therapeutic programs or broaden diagnostic portfolios. Competitive positioning thus rests on a combination of technological excellence, operational reliability, and the ability to form enduring client partnerships.

Practical and prioritized strategic actions for providers to shore up resilience, accelerate clinical integration, and differentiate through data, partnerships, and regulatory readiness

Industry leaders should pursue a set of pragmatic, executable actions to strengthen resilience, accelerate adoption, and capture differentiated value. First, prioritize investment in bioinformatics and data platform capabilities that enable robust interpretation and reporting across molecular and protein-based assays; these investments increase the utility of raw assay outputs and support clinical decision-making. Next, diversify sourcing strategies to reduce exposure to single-source suppliers and tariff-sensitive import pathways, and concurrently develop qualified alternate suppliers to preserve continuity of critical reagents and components.

Third, embed regulatory expertise and strong documentation practices into early assay development to shorten clearance timelines for companion diagnostics and high-complexity tests. Fourth, pursue collaborative partnerships with academic centers, hospitals, and CROs to co-develop assays that demonstrate clinical relevance and streamline patient access. Fifth, adopt modular service offerings that allow clients to mix and match analytical, clinical, and compliance services according to project scope, thereby improving commercial flexibility. In addition, invest in automation and LIMS adoption to improve throughput and reproducibility while reducing labor risk.

Finally, cultivate cross-functional talent with combined laboratory, regulatory, and data science experience, and incorporate sustainability and supply chain transparency into procurement decisions. Taken together, these measures will enhance operational stability, accelerate clinical impact, and strengthen commercial differentiation in a rapidly evolving landscape.

Robust methodological framework combining primary stakeholder interviews, multi-source secondary review, and technical triangulation to produce validated insights and identify evidence limitations

The research underpinning this executive summary integrates primary stakeholder engagement, multi-source secondary analysis, and rigorous triangulation to ensure reliability and relevance. Primary inputs included in-depth interviews with laboratory directors, clinical investigators, procurement leads, and technology suppliers to capture first-hand perspectives on operational challenges, technology adoption drivers, and regulatory pain points. These qualitative insights were complemented by a systematic review of peer-reviewed literature, regulatory guidance documents, technical white papers, and corporate disclosures to validate technology trends and standard-of-care shifts.

Analytical methods included technology assessments that compared analytic sensitivity, specificity, and workflow compatibility across platforms, as well as value-chain mapping to identify cost drivers and potential bottlenecks in supply and logistics. Segment mapping was applied to align service type, technology, application, and end-user considerations, and regional analyses drew on regulatory frameworks and published clinical adoption patterns. Throughout the process, findings were subjected to cross-validation with independent experts and technical reviewers to identify divergent perspectives and reconcile conflicting evidence.

Limitations of the approach include reliance on available published material and stakeholder willingness to disclose sensitive operational details; where direct data were not accessible, conservative interpretive frameworks and multiple corroborating sources were used to preserve integrity. The resulting synthesis is intended to inform strategic planning, operational adjustment, and partnership evaluation rather than to serve as a substitute for project-specific validation work.

Conclusive synthesis emphasizing alignment of technological investment, operational adaptability, and clinical partnership as central to sustained leadership in biomarker testing services

The coming phase for biomarker testing services will reward organizations that combine technical excellence with adaptive operational models and deep clinical partnerships. High-resolution molecular and proteomic platforms, supported by advanced analytics, are expanding the evidentiary bar for diagnostic utility and enabling more precise therapeutic alignment. At the same time, supply chain pressures and elevated regulatory expectations require providers to be deliberate about sourcing, validation pathways, and data governance.

Strategically, the imperative is to invest where differentiation delivers measurable clinical or developmental advantage-whether through faster turnaround for trial enrollment, superior analytic reproducibility that reduces downstream costs, or integrated reporting that enhances clinician confidence. Providers that can modularize offerings, demonstrate reproducibility across multiple platforms, and engage clinical partners early in validation stand to accelerate adoption in both diagnostic and drug development contexts. Furthermore, regional strategies should reflect regulatory idiosyncrasies and manufacturing opportunities that can reduce exposure to tariff- and logistics-driven disruption.

In summary, success rests on aligning technical investments with pragmatic operational choices and partnership models. Organizations that act on this alignment will be better equipped to translate biomarker science into reliable clinical services and strategic assets for pharmaceutical development.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rapid adoption of liquid biopsy technologies for early cancer detection at point of care
  • 5.2. Integration of AI and machine learning algorithms in novel biomarker discovery pipelines
  • 5.3. Expansion of multiplexed biomarker panel offerings for comprehensive disease profiling
  • 5.4. Growing emphasis on companion diagnostics to personalize oncology treatment pathways
  • 5.5. Development of point of care biomarker testing platforms for decentralized clinical trials
  • 5.6. Rising investments in genomic and proteomic biomarkers for precision immunotherapy selection
  • 5.7. Regulatory harmonization efforts accelerating global biomarker test approvals and market access
  • 5.8. Increasing adoption of digital pathology and image analysis in biomarker assay workflows
  • 5.9. Emergence of noninvasive wearable biosensor platforms for continuous biomarker monitoring
  • 5.10. Surging partnerships between biotech firms and diagnostic labs fueling high throughput biomarker screening

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Biomarker Testing Services Market, by Service Type

  • 8.1. Introduction
  • 8.2. Analytical Testing Services
  • 8.3. Clinical Testing Services
  • 8.4. Custom & Contract Services
  • 8.5. Regulatory & Compliance Services

9. Biomarker Testing Services Market, by Technology

  • 9.1. Introduction
  • 9.2. Bioinformatics & Data Platforms
  • 9.3. Cell-Based Assays
  • 9.4. Molecular Technologies
    • 9.4.1. In Situ Hybridization
      • 9.4.1.1. Chromogenic In Situ Hybridization (CISH)
      • 9.4.1.2. Fluorescence In Situ Hybridization (FISH)
    • 9.4.2. Microarrays
    • 9.4.3. Next-Generation Sequencing (NGS)
    • 9.4.4. Polymerase Chain Reaction (PCR)
      • 9.4.4.1. Digital PCR
      • 9.4.4.2. Quantitative Polymerase Chain Reaction (qPCR)
  • 9.5. Protein-Based Technologies
    • 9.5.1. Flow Cytometry
    • 9.5.2. Immunoassays
      • 9.5.2.1. Enzyme-Linked Immunosorbent Assay (ELISA)
      • 9.5.2.2. Western Blot
    • 9.5.3. Mass Spectrometry
      • 9.5.3.1. LC-MS/MS
      • 9.5.3.2. MALDI-TOF

10. Biomarker Testing Services Market, by Application

  • 10.1. Introduction
  • 10.2. Companion Diagnostics
    • 10.2.1. Oncology
    • 10.2.2. Personalized Medicine
  • 10.3. Disease Diagnosis
    • 10.3.1. Cardiovascular
    • 10.3.2. Infectious Disease
    • 10.3.3. Oncology
  • 10.4. Drug Development
    • 10.4.1. Clinical Trials
    • 10.4.2. Discovery
    • 10.4.3. Toxicology

11. Biomarker Testing Services Market, by End User

  • 11.1. Introduction
  • 11.2. Academic And Research Institutes
  • 11.3. Contract Research Organizations
  • 11.4. Hospitals And Diagnostics Labs
  • 11.5. Pharmaceutical And Biotechnology Companies

12. Americas Biomarker Testing Services Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Biomarker Testing Services Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Biomarker Testing Services Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Avid Bioservices, Inc.
    • 15.3.2. Agilent Technologies, Inc.
    • 15.3.3. BioAgilytix Labs
    • 15.3.4. BiomarkerBay B. V.
    • 15.3.5. Bristol Myers Squibb
    • 15.3.6. Eurofins Scientific SE
    • 15.3.7. F. Hoffmann-La Roche AG
    • 15.3.8. Icon PLC
    • 15.3.9. Intertek Group PLC
    • 15.3.10. IQVIA
    • 15.3.11. JSR Life Sciences, LLC
    • 15.3.12. Laboratory Corporation of America Holdings
    • 15.3.13. LGC Group
    • 15.3.14. Merck KGaA
    • 15.3.15. NeoGenomics Laboratories
    • 15.3.16. Parexel International Corporation
    • 15.3.17. SGS S.A.
    • 15.3.18. Shuwen Biotech Co., Ltd.
    • 15.3.19. Syneos Health
    • 15.3.20. Thermo Fisher Scientific, Inc.
    • 15.3.21. WuXi Biologics Inc.
    • 15.3.22. PerkinElmer Inc.
    • 15.3.23. KCAS Group
    • 15.3.24. Randox Laboratories
    • 15.3.25. Myriad Genetics, Inc.
    • 15.3.26. Bio-Rad Laboratories, Inc.

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. BIOMARKER TESTING SERVICES MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. BIOMARKER TESTING SERVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. BIOMARKER TESTING SERVICES MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. BIOMARKER TESTING SERVICES MARKET: RESEARCHAI
  • FIGURE 24. BIOMARKER TESTING SERVICES MARKET: RESEARCHSTATISTICS
  • FIGURE 25. BIOMARKER TESTING SERVICES MARKET: RESEARCHCONTACTS
  • FIGURE 26. BIOMARKER TESTING SERVICES MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. BIOMARKER TESTING SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL TESTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL TESTING SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CUSTOM & CONTRACT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CUSTOM & CONTRACT SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY REGULATORY & COMPLIANCE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY REGULATORY & COMPLIANCE SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOINFORMATICS & DATA PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOINFORMATICS & DATA PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CELL-BASED ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CELL-BASED ASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CHROMOGENIC IN SITU HYBRIDIZATION (CISH), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CHROMOGENIC IN SITU HYBRIDIZATION (CISH), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MICROARRAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY QUANTITATIVE POLYMERASE CHAIN REACTION (QPCR), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY QUANTITATIVE POLYMERASE CHAIN REACTION (QPCR), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY WESTERN BLOT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY LC-MS/MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY LC-MS/MS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MALDI-TOF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MALDI-TOF, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY TOXICOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY HOSPITALS AND DIAGNOSTICS LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY HOSPITALS AND DIAGNOSTICS LABS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 123. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
  • TABLE 127. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 129. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
  • TABLE 149. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 165. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 166. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 167. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 170. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 171. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 172. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 173. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2024 (USD MILLION)
  • TABLE 174. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2025-2030 (USD MILLION)
  • TABLE 175. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 176. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
  • TABLE 177. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 178. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 179. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 180. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 181. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 182. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
  • TABLE 183. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 185. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 186. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 187. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 188. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2025-2030 (USD MILLION)
  • TABLE 189. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 190. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 191. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 193. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 195. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 197. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 198. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 199. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2024 (USD MILLION)
  • TABLE 200. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2025-2030 (USD MILLION)
  • TABLE 201. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 202. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
  • TABLE 203. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 204. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 205. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 206. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 207. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 208. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
  • TABLE 209. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 211. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 212. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 213. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 214. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2025-2030 (USD MILLION)
  • TABLE 215. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 216. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 217. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 219. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 221. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 223. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 224. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 225. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2024 (USD MILLION)
  • TABLE 226. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2025-2030 (USD MILLION)
  • TABLE 227. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 228. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
  • TABLE 229. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 230. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 231. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 232. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 233. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 234. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
  • TABLE 235. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 237. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 238. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 239. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 240. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2025-2030 (USD MILLION)
  • TABLE 241. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 242. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 243. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 245. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 249. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 250. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 251. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2024 (USD MILLION)
  • TABLE 252. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2025-2030 (USD MILLION)
  • TABLE 253. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 254. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
  • TABLE 255. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 256. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 257. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 258. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 259. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 260. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
  • TABLE 261. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 263. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 264. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 265. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 266. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2025-2030 (USD MILLION)
  • TABLE 267. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 268. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 269. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY IN SITU HYBRIDIZATION, 2025-2030 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN-BASED TECHNOLOGIES, 2025-2030 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2025-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)

TABLE